CT.gov Metabolic Hiddenness
2026-03-29 | full-registry ct.gov audit | plots, figures, and e156 bundle
Series
Metabolic Dashboard

Metabolic hiddenness becomes clearer when sponsor class, phase structure, and stock are separated

The metabolic dashboard isolates family-specific sponsor mix, phase mix, and leading sponsors rather than folding them into an all-registry average.

Sponsor classes
Phases
Top sponsors
Family-specific stock

Dashboard

Metabolic hiddenness is driven by a mix of broad academic stock and substantial industry backlog rather than a single sponsor type.

How to read the dashboard
Eligible older
17,294
Metabolic studies
No-results rate
76.2%
2-year no-results
Largest phase bucket
9,811
nan
Top sponsor stock
391
Novo Nordisk A/S
Sponsor-class rates
METABOLIC SPONSOR CLASSES2-year no-results rate by sponsor class within metabolic studiesOTHER_GOV95.6%OTHER82.4%NIH63.1%INDUSTRY62.5%FED51.2%
OTHER_GOV remains near the top where present, but the broader metabolic burden is still shaped by the much larger OTHER and INDUSTRY blocks.
This is a family-specific rate view, so it should be read alongside the top-sponsor stock chart rather than as a standalone leaderboard.
Phase pattern
METABOLIC PHASES2-year no-results rate by phase inside the metabolic familyEARLY_PHASE188.5%nan84.7%PHASE183.5%PHASE2 | PHASE366.7%PHASE1 | PHASE265.9%PHASE464.7%PHASE258.6%PHASE352.5%
EARLY_PHASE1 is the quietest major phase inside the metabolic family on the no-results metric.
Phase structure matters because the family-level average can hide very different early-phase and late-phase behavior.
Largest sponsor stocks
METABOLIC TOP SPONSORSLead sponsors with the largest missing-results stock inside metabolic studiesNovo Nordisk A/S391Sanofi204AstraZeneca113Maastricht University Medical Center105University of Aarhus91Mayo Clinic84University of Copenhagen82Merck Sharp & Dohme LLC74GlaxoSmithKline74Chong Kun Dang Pharmaceutical71
Novo Nordisk A/S carries the largest named missing-results stock in this family at 391 studies.
The top-sponsor chart makes the family-specific backlog concrete instead of leaving it as a single family-wide percentage.
Read Across Projects

Across The Series

Each project isolates a different dimension of registry opacity, but the point is the contrast between them, not a single leaderboard.

Industry
CT.gov Industry Disclosure Gap

Industry-focused missing-results stock, sponsor backlogs, and structural sparsity inside CT.gov.

Sponsor Classes
CT.gov Sponsor-Class Hiddenness

Sponsor-class comparisons on rate, stock, and structural hiddenness rather than one flattened ranking.

Phases
CT.gov Phase Reporting Gap

Phase-by-phase disclosure gaps showing how silence changes along the development pathway.

Structural
CT.gov Structural Missingness

Field-level missingness across publication links, IPD statements, descriptions, and locations.

Visibility
CT.gov Evidence Visibility Gap

Results-plus-publication visibility states showing how many older trials are fully visible, partly visible, or ghosted.

Cohorts
CT.gov Completion Cohort Debt

Completion-era reporting debt showing how older eligible cohorts drift on no-results and ghost-protocol rates.

Conditions
CT.gov Condition Hiddenness Map

Keyword-classified therapeutic-area hiddenness mapping across common condition families.

Concentration
CT.gov Sponsor Backlog Concentration

Concentration and inequality analysis showing how much unresolved stock sits inside a thin sponsor slice.

Rule Eras
CT.gov Rule-Era Reporting Gap

Policy-era comparisons across pre-FDAAA, FDAAA, and later CT.gov completion cohorts.

PubMed Audit
CT.gov Publication Undercount Audit

Sample-based external PubMed NCT audit testing how often CT.gov no-link records hide an external paper trail.

Oncology
CT.gov Oncology Hiddenness

Oncology-specific CT.gov hiddenness showing where cancer-trial stock, phases, and sponsors still go quiet.

Cardiovascular
CT.gov Cardiovascular Hiddenness

Cardiovascular CT.gov hiddenness showing how heart and vascular studies remain quiet across major phases and sponsors.